This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Left main coronary artery disease (CAD) and diabetes pose significant challenges in cardiovascular care, often leading to adverse outcomes. Preliminary evidence from trials focusing on patients with multivessel disease has hinted at diabetes as a potential modifier of treatment outcomes.
Patients were categorized by diabetes status. Kaplan-Meier event rates, Cox model hazard ratios, and interactions were assessed.RESULTS:Among 4393 patients, 1104 (25.1%) had diabetes. Kaplan-Meier event rates, Cox model hazard ratios, and interactions were assessed.RESULTS:Among 4393 patients, 1104 (25.1%) had diabetes.
Sacharias von Kochpresented " Real-World Usage of Prevail Paclitaxel-Coated Balloon Compared with Other Contemporary Drug-Coated Balloons" This is atwo-year analysis from the Swedish Coronary Angiography and Angioplasty (SCAAR) Registry in more than 6,000 patients. Prevail DCB is limited to investigational use in the U.S.
National Inpatient Sample (NIS) database from 2009 to 2020, evaluating patients who presented with stroke from ICAD and were treated with angioplasty and stenting and analyzed presenting co-morbidities and patient outcomes. vs 7.9%), diabetes (33.6% There were significantly higher incidences in uncontrolled hypertension (28.2%
24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m. 12:15 p.m.
Sacharias von Kochpresented " Real-World Usage of Prevail Paclitaxel-Coated Balloon Compared with Other Contemporary Drug-Coated Balloons" This is atwo-year analysis from the Swedish Coronary Angiography and Angioplasty (SCAAR) Registry in more than 6,000 patients. Prevail DCB is limited to investigational use in the U.S.
Patient underwent emergent mechanical thrombectomy with ADAPT to TICI3 revascularization with future plan for possible angioplasty and stenting of R vertebral stenosis. CT perfusion was without mismatch. Subsequently admitted to neurocritical care unit and treated with dual antiplatelet therapy.
Marked differences can be seen in the prevalence of coronary artery stenosis at autopsy by age and gender. In 30-39 year old women the rate of coronary stenosis at autopsy was 5/1,545 (0.3%) while 60-69 year old men had a prevalence of 12%, almost 40 times higher. The results of this dataset by age and gender follow.
Preliminary data has also reported the 30‐day outcomes associated with intracranial stent placement for ICAD with RO‐ZES compared to results from the Stenting Versus Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial. The primary endpoint was composite of 1‐year stroke, ICH, and/or death.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content